Home › Funds › Trium Capital LLP › RNA
Trium Capital LLP position in RNA
ATRIUM THERAPEUTICS INC · Health Care
Trium Capital LLP reported holding 58,382 shares of RNA (ATRIUM THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$483K, representing 0.61% of its reported portfolio and ranking #24 among its reported holdings. Trium Capital LLP has disclosed RNA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-10-16 · Source: SEC EDGAR Form 13F-HR
How Trium Capital LLP's RNA position evolved
Trium Capital LLP first disclosed a stake in RNA in Q2 2026 at 113,278 shares (US$1.5M). Across 2 filings, Trium Capital LLP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 58,382 shares valued at US$483K — a reduction of -54,896 shares quarter over quarter.. Notable position changes include a 48% trim in Q3 2026 (shares rose 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 113.28K | $1.52M | New |
| Q3 2026 | 58.38K | $483.40K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RNA and 13F data
RNA (ATRIUM THERAPEUTICS INC) is a Health Care company. 116 other funds we track also report a position in RNA — the largest reported positions include Sessa Capital IM, L.P. (US$20.2M), CRCM LP (US$8.6M), TIG Advisors, LLC (US$7.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RNA
- Sessa Capital IM, L.P. 1.50M sh · $20.18M · Q2 2026
- CRCM LP 641.54K sh · $8.63M · Q2 2026
- TIG Advisors, LLC 561.53K sh · $7.55M · Q2 2026
- Arbiter Partners Capital Management LLC 261.29K sh · $3.51M · Q2 2026
- Slotnik Capital, LLC 237.64K sh · $3.20M · Q2 2026
- NEXPOINT ASSET MANAGEMENT, L.P. 150.03K sh · $2.02M · Q2 2026
- Bracebridge Capital, LLC 139.24K sh · $1.87M · Q2 2026
- Yakira Capital Management, Inc. 133.05K sh · $1.79M · Q2 2026
- Creek Drive Management Group LLC 127.60K sh · $1.72M · Q2 2026
- Athos Capital Ltd 107.97K sh · $1.45M · Q2 2026
- Marble Bar Asset Management LLP 103.85K sh · $1.40M · Q2 2026
- ALETHEA CAPITAL MANAGEMENT, LLC 43.76K sh · $588.54K · Q2 2026
More on Trium Capital LLP
FAQ
How long has Trium Capital LLP held RNA?
Trium Capital LLP has disclosed RNA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Trium Capital LLP's current position in RNA?
As of Q3 2026, Trium Capital LLP holds 58.38K shares of RNA (ATRIUM THERAPEUTICS INC), valued at $483.40K, representing 0.61% of its reported portfolio and ranking #24.
Has Trium Capital LLP been buying or selling RNA?
In the latest 13F filing (Q3 2026), Trium Capital LLP reduced its position in RNA.
Which other funds hold RNA?
Other major institutional holders of RNA include Sessa Capital IM, L.P., CRCM LP, TIG Advisors, LLC, among 116 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.